NDA 022460 · Waylis Therap
Jalyn
Dutasteride, Tamsulosin Hydrochloride · Oral · 5-alpha Reductase Inhibitor
Last checked: Nov 20, 2026Latest source record: Dec 29, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Jun 14, 2010
Approved uses
1
Original approval plus efficacy supplements
Registered trials
114
26 Phase 3, 7 recruiting
FAERS reports
1,046
405 serious, 58 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 9, 2026.
JALYN is a combination of dutasteride, a 5-alpha-reductase inhibitor, and tamsulosin, an alpha-adrenergic antagonist, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. ( 1.1 ) Limitations of Use: Dutasteride-containing products, including JALYN, are not approved for the prevention of prostate cancer. ( 1.2 ) 1.1 Benign Prostatic Hyperplasia (BPH) Treatment JALYN (dutasteride and tamsulosin hydrochloride) capsules are indicated for the treatment of symptomatic BPH in men with an enlarged prostate. 1.2 Limitations of Use Dutasteride-containing products, including JALYN, are not approved for the prevention of prostate cancer.
Mechanism: JALYN is a combination of 2 drugs with different mechanisms of action to improve symptoms in patients with BPH: dutasteride, a 5-alpha-reductase inhibitor, and tamsulosin, an antagonist of alpha 1A -adrenoreceptors. Dutasteride Dutasteride inhibits the conversion of testosterone to DHT. DHT is the androgen primarily responsible for the initial development and subsequent enlargement of the prostate gland. Testosterone is converted to DHT by the enzyme 5 alpha-reductase, which exists as 2 isoforms, type 1 and type 2. The type 2 isoenzyme is primarily active in the reproductive tissues, while...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 14, 2010 Original approval · Type 4 - New Combination Summary ReviewLetterLabel
1 products under this application
- JALYN · DUTASTERIDE 0.5MG; TAMSULOSIN HYDROCHLORIDE 0.4MG · CAPSULE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Dutasteride" as an intervention, any sponsor and status, largest first.
- "REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased RiskPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00056407 · 8,231 participants · Start Mar 2003 · Primary completion Jan 2009
Drug: Dutasteride; Placebo · For: Neoplasms, Prostate
Sites: Birmingham, Alabama; Homewood, Alabama; Huntsville, Alabama · 932 sites in all
- Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination TreatmentPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00090103 · 4,844 participants · Start Nov 2003 · Primary completion Apr 2009
Drug: dutasteride 0.5mg once daily for 4 years; tamsulosin 0.4mg once daily for 4 years · For: Prostatic Hyperplasia
Sites: Birmingham, Alabama; Columbiana, Alabama; Hoover, Alabama · 503 sites in all
- Dutasteride Versus Placebo and Finasteride in Men With Androgenetic AlopeciaPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01231607 · 917 participants · Start Oct 28, 2010 · Primary completion Feb 1, 2012
Drug: 1mg Finasteride active; 0.02mg dutasteride and 4 more · For: Androgenetic Alopecia
Sites: CABA, Argentina; Ciudad Autonoma de Buenos Aires, Argentina; La Boca, Argentina · 39 sites in all
GlaxoSmithKlineGSK (GSK)
NCT01294592 · 742 participants · Start Dec 22, 2010 · Primary completion Oct 17, 2013
Drug: Dutasteride plus tamsulosin; tamsulosin · For: Prostatic Hyperplasia
Sites: Aigrefeuille-sur-Maine, France; Angers, France; Corsept, France · 80 sites in all
- Efficacy and Safety of DKF-313 in Patients With Benign Prostatic HyperplasiaPivotal-lookingCompleted
Dongkook Pharmaceutical Co., Ltd.Industry
NCT04947631 · 667 participants · Start Jul 27, 2021 · Primary completion Jun 12, 2023
Drug: DKF-313; Dutasteride and 4 more · For: Benign Prostatic Hyperplasia
Sites: Seoul, South Korea
- Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic HyperplasiaPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT02058368 · 607 participants · Start Feb 10, 2014 · Primary completion Mar 3, 2017
Drug: Dutasteride 0.5mg capsules; Dutasteride placebo capsules and 2 more · For: Prostatic Hyperplasia
Sites: Xiame, China; Guangzhou, China; Wuhan, China · 46 sites in all
- Prospective Sexual Function Study for BPH SubjectsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01777269 · 489 participants · Start Feb 18, 2013 · Primary completion Apr 5, 2016
Drug: Dutasteride plus tamsulosin; Placebo · For: Prostatic Hyperplasia
Sites: Randwick, Australia; Sydney, Australia; Wahroonga, Australia · 67 sites in all
- Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate CancerPivotal-lookingCompleted
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityAcademic, hospital or other
NCT00398281 · 450 participants (planned) · Start Nov 2006 · Primary completion Jul 2010
Drug: dutasteride · For: Prostate Cancer
Sites: Philadelphia, Pennsylvania
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective90
- dizziness72
- rash43
- diarrhoea39
- fatigue39
- dyspnoea35
- fall32
- erectile dysfunction30
- pruritus29
- headache25
- hypotension25
- asthenia23
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 12 |
| 2011 | 200 |
| 2012 | 187 |
| 2013 | 109 |
| 2014 | 105 |
| 2015 | 111 |
| 2016 | 96 |
| 2017 | 39 |
| 2018 | 51 |
| 2019 | 39 |
| 2020 | 32 |
| 2021 | 17 |
| 2022 | 12 |
| 2023 | 5 |
| 2024 | 14 |
| 2025 | 6 |
| 2026 | 11 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Jalyn (Dutasteride/Tamsulosin HCl)
2024 spending
$32K
Beneficiaries
21
29 claims
Per beneficiary
$1,535
$21.78 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,103,155 |
| 2021 | $935,195 |
| 2022 | $909,866 |
| 2023 | $1,119,872 |
| 2024 | $32,232 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Management of androgenic alopecia: a systematic review of the literature.
Rosenthal A, Conde G, Greco JF, et al. · J Cosmet Laser Ther 2024 · Systematic Review
- Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis.
Lee S, Lee YB, Choe SJ, et al. · Acta Derm Venereol 2019 · Meta-Analysis, Systematic Review
- Systematic review of mesotherapy: a novel avenue for the treatment of hair loss.
Gupta AK, Polla Ravi S, Wang T, et al. · J Dermatolog Treat 2023 · Systematic Review
- Injectable Therapy for Androgenetic Alopecia: A Systematic Review.
Beer J, Boghosian T, Mendez H, et al. · Dermatol Surg 2026 · Systematic Review
- Interventions for female pattern hair loss.
van Zuuren EJ, Fedorowicz Z, Schoones J · Cochrane Database Syst Rev 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis.
Gupta AK, Mays RR, Dotzert MS, et al. · J Eur Acad Dermatol Venereol 2018 · Systematic Review, Network Meta-Analysis
Sponsor: Waylis Therap
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.